Showing 1 - 2 results of 2 for search 'Masahiro Hatooka', query time: 0.02s Refine Results
  1. 1
    Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial

    Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial by Masahiro Hatooka, Tomokazu Kawaoka, Hiroshi Aikata, Yuki Inagaki, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Kazuo Awai, Keiichi Masaki, Koji Waki, Hirotaka Kohno, Hiroshi Kohno, Takashi Moriya, Yuko Nagaoki, Toru Tamura, Hajime Amano, Yoshio Katamura, Kazuaki Chayama

    Published 2018-06-01
    Get full text
    Article
  2. 2
    The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.

    The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. by Yuko Nagaoki, Michio Imamura, Hiroshi Aikata, Kana Daijo, Yuji Teraoka, Fumi Honda, Yuki Nakamura, Masahiro Hatooka, Reona Morio, Kei Morio, Hiromi Kan, Hatsue Fujino, Tomoki Kobayashi, Keiichi Masaki, Atsushi Ono, Takashi Nakahara, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Yoshiiku Kawakami, C Nelson Hayes, Daiki Miki, Hidenori Ochi, Kazuaki Chayama

    Published 2017-01-01
    Get full text
    Article

Search Tools: